10-Q Filing

BIO-PATH HOLDINGS, INC. CIK: 1133818 Q1 2016

Filing Information

Form Type	10-Q
Accession Number	`0001144204-16-100471`
Period End Date	20160331
Filing Date	20160510
Fiscal Year	2016
Fiscal Period	Q1
XBRL Instance	bpth-20160331.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 60 Income Statement 20 Cash Flow Statement 26

Balance Sheet 60 line items

Line Item	Tag	Value	Unit	Period
Preferred Stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred Stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Cash	`Cash`	$8.85M	USD	Point-in-time
Cash	`Cash`	$13.86M	USD	Point-in-time
Cash	`Cash`	$6.47M	USD	Point-in-time
Cash	`Cash`	$12.45M	USD	Point-in-time
Preferred Stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred Stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Prepaid drug product for testing	`OtherInventory`	$560.00K	USD	Point-in-time
Preferred Stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Prepaid drug product for testing	`OtherInventory`	$611.00K	USD	Point-in-time
Preferred Stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$179.00K	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$750.00K	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$7.83M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$9.59M	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	89.76M	shares	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	89.76M	shares	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	89.76M	shares	Point-in-time
Furniture, fixtures & equipment	`PropertyPlantAndEquipmentGross`	$123.00K	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	89.76M	shares	Point-in-time
Furniture, fixtures & equipment	`PropertyPlantAndEquipmentGross`	$123.00K	USD	Point-in-time
Less Accumulated Depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$51.00K	USD	Point-in-time
Less Accumulated Depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$61.00K	USD	Point-in-time
Property, Plant and Equipment, Net	`PropertyPlantAndEquipmentNet`	$62.00K	USD	Point-in-time
Property, Plant and Equipment, Net	`PropertyPlantAndEquipmentNet`	$72.00K	USD	Point-in-time
Technology licenses	`FiniteLivedLicenseAgreementsGross`	$2.50M	USD	Point-in-time
Technology licenses	`FiniteLivedLicenseAgreementsGross`	$2.50M	USD	Point-in-time
Less Accumulated Amortization	`FiniteLivedIntangibleAssetsAccumulatedAmortization`	$1.45M	USD	Point-in-time
Less Accumulated Amortization	`FiniteLivedIntangibleAssetsAccumulatedAmortization`	$1.41M	USD	Point-in-time
Intangible Assets, Net (Excluding Goodwill), Total	`IntangibleAssetsNetExcludingGoodwill`	$1.05M	USD	Point-in-time
Intangible Assets, Net (Excluding Goodwill), Total	`IntangibleAssetsNetExcludingGoodwill`	$1.09M	USD	Point-in-time
Total Assets	`Assets`	$8.95M	USD	Point-in-time
Total Assets	`Assets`	$10.76M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$54.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$201.00K	USD	Point-in-time
Accrued expense	`AccruedLiabilitiesCurrent`	$883.00K	USD	Point-in-time
Accrued expense	`AccruedLiabilitiesCurrent`	$699.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$900.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$937.00K	USD	Point-in-time
Total Liabilities	`Liabilities`	$900.00K	USD	Point-in-time
Total Liabilities	`Liabilities`	$937.00K	USD	Point-in-time
Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common Stock, $.001 par value, 200,000,000 shares authorized 89,762,872 and 89,762,872 shares issued and outstanding as of 3/31/16 and 12/31/15, respectively	`CommonStockValue`	$90.00K	USD	Point-in-time
Common Stock, $.001 par value, 200,000,000 shares authorized 89,762,872 and 89,762,872 shares issued and outstanding as of 3/31/16 and 12/31/15, respectively	`CommonStockValue`	$90.00K	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$35.21M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$35.11M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-27.25M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-25.38M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$8.05M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$9.82M	USD	Point-in-time
Total Liabilities & Shareholders' Equity	`LiabilitiesAndStockholdersEquity`	$10.76M	USD	Point-in-time
Total Liabilities & Shareholders' Equity	`LiabilitiesAndStockholdersEquity`	$8.95M	USD	Point-in-time

Income Statement 20 line items

Line Item	Tag	Value	Unit	Period
Revenue	`Revenues`	-	USD	1 Quarter
Revenue	`Revenues`	-	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.02M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$593.00K	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$849.00K	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$786.00K	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$1.87M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$1.38M	USD	1 Quarter
Net operating loss	`OperatingIncomeLoss`	$-1.38M	USD	1 Quarter
Net operating loss	`OperatingIncomeLoss`	$-1.87M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$2.00K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$4.00K	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$2.00K	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$4.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-1.38M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-1.87M	USD	1 Quarter
Net loss per share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.02	USD	1 Quarter
Net loss per share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.02	USD	1 Quarter
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	89,763.00	shares	1 Quarter
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	89,763.00	shares	1 Quarter

Cash Flow Statement 26 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-1.38M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-1.87M	USD	1 Quarter
Amortization	`AdjustmentForAmortization`	$40.00K	USD	1 Quarter
Amortization	`AdjustmentForAmortization`	$40.00K	USD	1 Quarter
Depreciation	`Depreciation`	$10.00K	USD	1 Quarter
Depreciation	`Depreciation`	$10.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$95.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$92.00K	USD	1 Quarter
Prepaid drug product for testing	`IncreaseDecreaseInInventories`	$51.00K	USD	1 Quarter
Prepaid drug product for testing	`IncreaseDecreaseInInventories`	$204.00K	USD	1 Quarter
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$571.00K	USD	1 Quarter
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$22.00K	USD	1 Quarter
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-37.00K	USD	1 Quarter
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$54.00K	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-2.38M	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-1.41M	USD	1 Quarter
Net increase (decrease) in cash	`CashPeriodIncreaseDecrease`	$-2.38M	USD	1 Quarter
Net increase (decrease) in cash	`CashPeriodIncreaseDecrease`	$-1.41M	USD	1 Quarter
Cash, beginning of period	`Cash`	$8.85M	USD	Point-in-time
Cash, beginning of period	`Cash`	$13.86M	USD	Point-in-time
Cash, beginning of period	`Cash`	$6.47M	USD	Point-in-time
Cash, beginning of period	`Cash`	$12.45M	USD	Point-in-time
Cash, end of period	`Cash`	$8.85M	USD	Point-in-time
Cash, end of period	`Cash`	$13.86M	USD	Point-in-time
Cash, end of period	`Cash`	$6.47M	USD	Point-in-time
Cash, end of period	`Cash`	$12.45M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.